The government has released a tentative list of priority groups to receive a successful coronavirus vaccine.
Talks were held to decide who should receive the potentially life-saving shock first.
An independent report by the Joint Vaccination and Immunization Committee outlined the potential use of a safe and effective vaccine should it be approved for use in the UK.
Potential priority ratings are based on preliminary information on vaccines under development and preliminary deadlines for vaccine availability and are subject to change, the reports LiverpoolEcho.
The committee agreed that a simple age-based criterion would most likely result in faster delivery and better uptake in those at highest risk.
The details of a vaccine and other factors determine whether health and social workers should be prioritized before, alongside, or among those at highest risk of Covid-19.
A preliminary priority ranking is:
- older adults living in a nursing home and nursing home workers
- all these 80s and older as well as health and social workers
- all these 75 years and older
- all these 70 years and older
- all these 65 years and older
- High risk adults under 65 years of age
- Medium risk adults under 65 years of age
- all these 60 years and older
- all these 55 years and older
- all these 50 years and older
- Rest of the population (priority to be determined)
This could change significantly if the first available vaccines for older adults were not considered appropriate or effective.
Meanwhile, a Chinese pharmaceutical company has announced that the coronavirus vaccine it is developing should be ready for global distribution by early 2021.
Yin Weidong, the managing director of SinoVac, promised to apply to the US Food and Drug Administration to sell CoronaVac there when it passes its third and final round of human testing.
He said: “At the very beginning, our strategy for China and Wuhan was designed. Shortly afterwards, in June and July, we adjusted our strategy to face the world.
“Our goal is to make the vaccine available to the world, including the US, EU and others.”
Strict regulations have previously blocked sales of Chinese vaccines in the US, EU, Japan and Australia – but Mr. Yin claimed these could be relaxed.